ow dose DEC as an alternative to current dose used in Lymphatic Filariasis program
Phase 4
Completed
- Registration Number
- CTRI/2014/02/004375
- Lead Sponsor
- Regional Medical Research Centre ICMR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 900
Inclusion Criteria
More than 5 years one site regimen consisting 100 mg DEC second site regimen consisting of 200 mg DEC and third site regimen consisting of 300 mg DEC annually oral single dose for 2 to 5 years child all sites given 100 mg DEC annually oral single dose
Exclusion Criteria
More than 2 yrs, pregnant women, seriously ill subjects
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To compare the efficacy of single dose DEC of 100mg strength in mf suppression with either 200mg or 300mg given uniformly in all age groups as annual doses of MDA in 3 different endemic communities. <br/ ><br>2.To compare the frequency and intensity of side reaction of DEC observed with three different strengths given as annual dose of MDA. <br/ ><br>3.To observe the effect on vector transmission in three different communities following annual uniform doses of DEC of varied strength. <br/ ><br>Timepoint: Baseline, 4, 12, 24, 36, 48 and 60 months
- Secondary Outcome Measures
Name Time Method a)Mf suppression effect of 100mg, 200mg or 300mg DEC given as single annual dose of MDA. <br/ ><br>b)Effect on community load of microfilarimia <br/ ><br>c)Effect of low dose DEC of 100 mg compared to either 200 or 300mg in higher age groups 6-14 or above 14 yrs. <br/ ><br>Timepoint: Baseline, 4, 12, 24, 36, 48 and 60 months